Table 1.

General characteristics of cohort.

Patients, n499
Age, yrs, mean (SD)57.2 (29.3)
Male/female, %17.1/82.9
Diagnosis, n (%)
  Rheumatoid arthritis361 (72.3)
  Axial spondyloarthritis101 (20.2)
  Psoriatic arthritis30 (6)
  JIA7 (1.4)
Antibody status, %
  RA with RF- or ACPA-positive63.7
  ANA in cohort6.3
Disease duration, yrs, mean (SD)15.8 (11.2)
Prior no. biologics, IV or SC, mean (95% CI)1.8 (1.6–2.3)
Concomitant therapy, overall/RA patients, n (%)
  Methotrexate218 (43.7)/193 (53.4)
  Other sDMARD39 (7.8)/30 (8.8)
  Corticosteroids246 (49.4)/179 (49.5)
  • JIA: juvenile idiopathic arthritis; RA: rheumatoid arthritis; RF: rheumatoid factor; ACPA: anticitrullinated protein antibody; ANA: antinuclear antibody; IV: intravenous; SC: subcutaneous; sDMARD: synthetic disease-modifying antirheumatic drug.